A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part)

BACKGROUND: Limited treatment options exist for patients with mild-to-moderate coronavirus disease 2019 (COVID-19), irrespective of vaccination history or risk status. Ensitrelvir is a novel oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3C-like (3CL) protease inhibitor. While pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Yotsuyanagi, Hiroshi, Ohmagari, Norio, Doi, Yohei, Imamura, Takumi, Sonoyama, Takuhiro, Ichihashi, Genki, Sanaki, Takao, Tsuge, Yuko, Uehara, Takeki, Mukae, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
4900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949372/
https://www.ncbi.nlm.nih.gov/pubmed/36827007
http://dx.doi.org/10.1097/MD.0000000000033024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949372/
https://www.ncbi.nlm.nih.gov/pubmed/36827007
http://dx.doi.org/10.1097/MD.0000000000033024

Ejemplares similares